ArticleArchives of microbiology2026
Recombinant BCG-Ag85A enhances antitumor immunity and controls melanoma progression through multimodal immune activation in mice.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is an aggressive form of skin cancer characterized by high metastatic potential and increasing incidence and mortality worldwide. Although significant advances have been achieved with immune checkpoint inhibitors and targeted therapies, effective preventive and long-term therapeutic strategies remain limited. Bacillus Calmette-Guérin (BCG), widely used in bladder cancer immunotherapy, exhibits potent immunostimulatory properties and has emerged as a promising platform for recombinant cancer vaccines. Among the candidate antigens, Antigen 85A (Ag85A), derived from Mycobacterium bovis, is notable for its strong immunogenicity and ability to induce robust Th1-mediated cellular immune responses. In this study, recombinant BCG strains overexpressing efficacy was evaluated in melanoma models in vitro and in vivo. Gene expression analysis by RT-qPCR revealed that rBCG-Ag85A induced systemic immune activation, characterized by increased Il1B and Trl4 expression in splenocytes. In tumor tissues, rBCG-Ag85A significantly upregulated genes associated with apoptosis (Bax, Bcl2), oxidative stress (Sod1, Cat), inflammatory and immune signaling pathways (Tlr4, Nfkb, Il12, Il1b, Casp1), and modulation of pathways involved in cellular metabolism (Mtor) indicating enhanced modulation of the tumor microenvironment. Functionally, these molecular and immunological effects were associated with reduced tumor progression, slower tumor growth, and improved survival in B16F10 melanoma-bearing mice. Collectively, these findings demonstrate that rBCG-Ag85A promotes multifaceted antitumor activity through the modulation of apoptosis, inflammation and oxidative stress-related gene expression, highlighting its potential as a promising prophylactic vaccine strategy to prevent cutaneous malignant melanoma and supporting future studies aimed at elucidating the immune cell populations involved and optimizing combinatorial therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.